Insider Purchases: Inside the Buy
Tag: Speculative Stocks
IPX Stock: America’s Titanium Comeback—or a Costly Experiment? 🦾
IperionX is betting on a U.S. titanium comeback. With government backing and disruptive tech, the upside is huge—but so are the risks.
1 comment
|
Kosmos Energy (KOS) Analysis 2026: Insider Buying vs. Shareholder Dilution—Is the Bottom In?
Kosmos Energy insiders just bought millions of dollars of stock after issuing nearly 100 million new shares. Is this a turnaround signal… or a classic case of debt-driven dilution? Let’s break down the risks, the oil assets, and the “sneaky management” dilemma.
Insider Buys Shares of Mainz Biomed: Promising Science, Precarious Finances
Mainz Biomed’s cancer-screening science is compelling — and an insider just bought big. But with heavy losses, dilution risk, and a going-concern warning, MYNZ is a biotech moonshot best approached with extreme caution.
Insiders Buy Airship AI; Should You Invest Or Just Do Surveillance?
Insiders are buying Airship AI — but this micro-cap surveillance play comes with heavy risks, short pressure, and execution hurdles. Speculative by design. 🕵️♂️
Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?
NTLA is the kind of stock that tests both your thesis and your pulse. Short interest sits around 36%, the FDA put a key trial on hold, and yet directors just bought ~$2.4M in shares. Here’s the fun-but-serious update on the squeeze setup, the catalysts, and the risks.
AirJoule Technologies (AIRJ): Water From Thin Air — and a Stock With Serious Upside?
AirJoule is building technology to extract pure water from air using waste heat — targeting data centers, industry, and defense. The vision is compelling, the partnerships are real, and the risks are just as real. This is a venture-style bet, not a safe harbor.
Biohaven Just Went Through Hell — But Its CEO and Directors Still See an Angel
Biohaven’s stock plunged after a brutal FDA rejection — but insiders didn’t blink. They bought millions of dollars’ worth of shares, doubled down on their pipeline, and kickstarted a leaner, more focused strategy. Bold turnaround play or biotech heartburn waiting to happen? Here's the FUNanc1al deep dive.
Tilray of Sunshine: CEO Bought Shares Weeks Ago — and Now Earnings Are Finally Rolling In
Tilray finally posted profits and a healthy cash flow — and insiders bought in early. Could this be the long-awaited turnaround, or just another puff of smoke?
Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!
AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.
Eastman Kodak (KODK): Insider Buys, Debt Drama & a Pivot to Pills?!
Eastman Kodak insiders are snapping up shares, with CEO Jim Continenza leading the charge. But Kodak’s finances are shaky, its debt heavy, and its pivot to pharmaceuticals uncertain. High risk, high reward — or just a faded picture?